Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-4/RTOG-3515: durvalumab or placebo after SBRT in unresected stage I/II NSCLC, with an EGFR-mutant osimertinib cohort
MOH_2019-06-02_007173Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Imfinzi after SBRT, Placebo after SBRT and Tagrisso cohort after SBRT (3 arms). Started Mar 2019; status: active, not recruiting.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2019-06-02_007173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-02_007173.